Conformational flexibility and packing plausibility of Repaglinide (cas 108157-52-4) polymorphs
-
Add time:08/25/2019 Source:sciencedirect.com
The present manuscript highlights the structural insight into the Repaglinide (cas 108157-52-4) polymorphs. The experimental screening for the possible crystal forms were carried out using various solvents, which generated three forms. The crystal structure of Form II and III was determined using PXRD pattern whereas structural analysis of Form I has already been reported. Form I, II and II was found to exist in P212121, PNA21 and P21/c space groups respectively. Conformational analysis was performed to account the conformational flexibility of RPG. The obtained conformers were further utilized to obtain the information about the crystal packing pattern of RPG polymorphs by polymorph prediction module. The lattice energy landscape, depicting the relationship between lattice energy and density of the polymorphs has been obtained for various possible polymorphs. The experimentally isolated polymorphs were successfully fitted into lattice energy landscape.
We also recommend Trading Suppliers and Manufacturers of Repaglinide (cas 108157-52-4). Pls Click Website Link as below: cas 108157-52-4 suppliers
Prev:Identification of Repaglinide (cas 108157-52-4) as a therapeutic drug for glioblastoma multiforme
Next:Repaglinide (cas 108157-52-4)☆) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- A floating-type dosage form of Repaglinide (cas 108157-52-4) in polycarbonate microspheres08/31/2019
- Development of Repaglinide (cas 108157-52-4) microspheres using novel acetylated starches of bitter and Chinese yams as polymers08/30/2019
- Dual crosslinked pectin–alginate network as sustained release hydrophilic matrix for Repaglinide (cas 108157-52-4)08/29/2019
- The first insight into the supramolecular structures of popular drug Repaglinide (cas 108157-52-4): Focus on intermolecular interactions in antidiabetic agents08/28/2019
- Conformation of Repaglinide (cas 108157-52-4): A solvent dependent structure08/27/2019
- Repaglinide (cas 108157-52-4)☆08/26/2019
- Identification of Repaglinide (cas 108157-52-4) as a therapeutic drug for glioblastoma multiforme08/24/2019
- Endocrine pharmacologyCharacteristics of Repaglinide (cas 108157-52-4) effects on insulin secretion08/23/2019
- ArticleThe Structural Basis for the Binding of Repaglinide (cas 108157-52-4) to the Pancreatic KATP Channel08/22/2019


